Caribou Biosciences, Inc. Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost
Caribou Biosciences, Inc. (CRBU) had Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost of $130.49 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Debt and Equity Securities › Available-for-Sale Securities, Debt Maturities
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis · last filed 2026-03-05
- 2025-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $130.49M.
- 2025-03-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $183.03M.
- 2024-12-31: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $233.09M.
- 2024-09-30: Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost $249.04M.
| Period end | Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost |
|---|---|
| 2025-12-31 | $130.49M 10-K · filed 2026-03-05 |
| 2025-03-31 | $183.03M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $233.09M 10-K · filed 2025-03-10 |
| 2024-09-30 | $249.04M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $273.91M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $296.53M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $321.24M 10-K · filed 2024-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |